Universita' Degli Studi Di Torino — Sponsor Intelligence | 7 EU Trials

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

2 Completed trials

2 Countries active

13 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 5 Phase IV: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Critical illness 1 Prostate cancer metastatic 1 Non-small cell lung cancer stage IIIB 1 Non-small cell lung cancer stage IIIA 1

Top IMPs

LENALIDOMIDE 2 APALUTAMIDE 1 BORTEZOMIB 1 CARFILZOMIB 1 DARATUMUMAB 1 DEXAMETHASONE SODIUM PHOSPHATE 1 DOSTARLIMAB 1 MELPHALAN 1 NIRAPARIB TOSILATE MONOHYDRATE 1 NORADRENALINE TARTRATE 1 PEMBROLIZUMAB 1 PREDNISONE 1

All trials

7 total

A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending

2024-514701-57-01 Phase II 1 country PEMBROLIZUMAB
A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma posit… Pending

2024-515555-38-01 Phase II 1 country DOSTARLIMAB
A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastat… Pending

2024-519519-32-00 Phase II 1 country NIRAPARIB TOSILATE MONOHYDRATE
Preventing caRdiovascular collapsE with VasoprEssors duriNg Tracheal IntubatiON: The PREVENTION Randomized Controlled Trial (PREVENTION tria… Recruiting

2023-503895-25-00 Phase III 2 countries NORADRENALINE TARTRATE
Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and s… Recruiting

2024-515049-41-00 Phase II 1 country APALUTAMIDE
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM… Ended

2024-512049-17-00 Phase IV 1 country BORTEZOMIB; DARATUMUMAB; DEXAMETHASONE SODIUM PHOSPHATE; LENALIDOMIDE; MELPHALAN…
Multicenter trial with carfilzomib combined with lenalidomide or cyclophopshamide with or without autologous transplant in newly diagnosed m… Ended

2024-516630-35-01 Phase II 1 country CARFILZOMIB; LENALIDOMIDE

Showing 1–7 of 7 trials

← All sponsors A–Z